Brain p3-Alcβ peptide restores neuronal viability impaired by Alzheimer's amyloid β-peptide.


Journal

EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380

Informations de publication

Date de publication:
08 05 2023
Historique:
revised: 14 03 2023
received: 16 10 2022
accepted: 14 03 2023
medline: 9 5 2023
pubmed: 31 3 2023
entrez: 30 3 2023
Statut: ppublish

Résumé

We propose a new therapeutic strategy for Alzheimer's disease (AD). Brain peptide p3-Alcβ37 is generated from the neuronal protein alcadein β through cleavage of γ-secretase, similar to the generation of amyloid β (Aβ) derived from Aβ-protein precursor/APP. Neurotoxicity by Aβ oligomers (Aβo) is the prime cause prior to the loss of brain function in AD. We found that p3-Alcβ37 and its shorter peptide p3-Alcβ9-19 enhanced the mitochondrial activity of neurons and protected neurons against Aβo-induced toxicity. This is due to the suppression of the Aβo-mediated excessive Ca

Identifiants

pubmed: 36994913
doi: 10.15252/emmm.202217052
pmc: PMC10165357
doi:

Substances chimiques

Amyloid beta-Peptides 0
peptide P3 0
Amyloid beta-Protein Precursor 0
Amyloid Precursor Protein Secretases EC 3.4.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e17052

Informations de copyright

© 2023 The Authors. Published under the terms of the CC BY 4.0 license.

Références

Ann Neurol. 2011 Jun;69(6):1026-31
pubmed: 21681798
J Neurochem. 2012 Oct;123(1):21-8
pubmed: 22817324
Eur J Pharm Sci. 2022 Mar 1;170:106096
pubmed: 34929301
Hum Mol Genet. 2012 Jul 1;21(13):2845-54
pubmed: 22434822
J Biol Chem. 2008 Oct 31;283(44):29615-9
pubmed: 18650430
J Biol Chem. 2003 Dec 5;278(49):49448-58
pubmed: 12972431
Curr Genet Med Rep. 2018;6(1):1-10
pubmed: 29564191
Neuron. 2007 Feb 15;53(4):549-62
pubmed: 17296556
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Nat Rev Neurosci. 2010 Oct;11(10):682-96
pubmed: 20842175
Mol Neurobiol. 2017 Oct;54(8):5894-5904
pubmed: 27660276
Mol Biol Cell. 2017 Dec 15;28(26):3844-3856
pubmed: 29093024
J Neurosci. 1993 May;13(5):2085-104
pubmed: 8097530
J Nucl Med. 2014 Mar;55(3):473-80
pubmed: 24470629
Neuropsychologia. 2015 Nov;78:10-7
pubmed: 26415670
J Labelled Comp Radiopharm. 2013 Sep;56(11):553-61
pubmed: 24285187
J Nucl Med. 2007 Apr;48(4):573-81
pubmed: 17401094
J Biol Chem. 2015 Jan 9;290(2):987-95
pubmed: 25406318
Science. 1999 Oct 22;286(5440):735-41
pubmed: 10531052
J Biol Chem. 2014 Dec 12;289(50):34530-42
pubmed: 25352602
J Biol Chem. 2002 Aug 30;277(35):32046-53
pubmed: 12058030
Nat Neurosci. 2012 Jan 29;15(3):349-57
pubmed: 22286176
Science. 2002 Jul 19;297(5580):353-6
pubmed: 12130773
Cell Rep. 2014 Mar 27;6(6):1096-1109
pubmed: 24613359
J Biol Chem. 2009 Dec 25;284(52):36024-36033
pubmed: 19864413
J Biol Chem. 1999 Sep 3;274(36):25945-52
pubmed: 10464339
Redox Biol. 2018 Apr;14:450-464
pubmed: 29080524
Mol Cell Neurosci. 2002 Nov;21(3):393-409
pubmed: 12498782
BMJ Neurol Open. 2022 Aug 10;4(2):e000321
pubmed: 36046332
Neuropsychopharmacology. 2016 Feb;41(3):802-10
pubmed: 26171716
Nature. 1998 Jan 22;391(6665):387-90
pubmed: 9450754
Mol Biol Cell. 2006 Aug;17(8):3651-63
pubmed: 16760430
Traffic. 2012 Jun;13(6):834-48
pubmed: 22404616
J Neuroinflammation. 2019 Nov 10;16(1):208
pubmed: 31707986
PLoS One. 2016 Jan 20;11(1):e0147134
pubmed: 26788729
Traffic. 2009 May;10(5):572-89
pubmed: 19192245
J Vis Exp. 2008 Nov 10;(21):
pubmed: 19066529
J Biol Chem. 2004 Jun 4;279(23):24343-54
pubmed: 15037614
EMBO Mol Med. 2023 May 8;15(5):e17052
pubmed: 36994913
Nat Neurosci. 2014 May;17(5):661-3
pubmed: 24728269
J Neurochem. 2019 May;149(4):452-470
pubmed: 30851210
Mol Biol Cell. 2014 Nov 5;25(22):3569-80
pubmed: 25165140
Ann Neurol. 1999 Dec;46(6):860-6
pubmed: 10589538
Neurobiol Aging. 2023 Mar;123:63-74
pubmed: 36638682
Neuron. 2013 Oct 2;80(1):113-28
pubmed: 24094106
EMBO J. 2007 Mar 21;26(6):1475-86
pubmed: 17332754
Alzheimers Dement (N Y). 2019 Nov 07;5:740-750
pubmed: 31754625
J Neuroinflammation. 2017 Mar 29;14(1):69
pubmed: 28356120
J Biol Chem. 2020 Jul 10;295(28):9650-9662
pubmed: 32467230

Auteurs

Saori Hata (S)

Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan.

Haruka Saito (H)

Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Advanced Prevention and Research Laboratory for Dementia, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Takeharu Kakiuchi (T)

Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Japan.

Dai Fukumoto (D)

Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Japan.

Shigeyuki Yamamoto (S)

Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Japan.

Kensaku Kasuga (K)

Molecular Genetics, Niigata University Brain Research Institute, Nigata, Japan.

Ayano Kimura (A)

Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Koichi Moteki (K)

Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Advanced Prevention and Research Laboratory for Dementia, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Ruriko Abe (R)

Advanced Prevention and Research Laboratory for Dementia, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Shungo Adachi (S)

Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan.

Shoich Kinoshita (S)

Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Advanced Prevention and Research Laboratory for Dementia, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Kumiko Yoshizawa-Kumagaye (K)

Peptide Institute, Inc., Ibaraki, Japan.

Hideki Nishio (H)

Peptide Institute, Inc., Ibaraki, Japan.

Takashi Saito (T)

Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Institute, Wako, Japan.
Department of Neurocognitive Science, Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Takaomi C Saido (TC)

Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science Institute, Wako, Japan.

Tohru Yamamoto (T)

Department of Molecular Neurobiology, Factory of Medicine, Kagawa University, Takamatsu, Japan.

Masaki Nishimura (M)

Molecular Neuroscience Research Center, Shiga University of Medical Science, Shiga, Japan.

Hidenori Taru (H)

Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Advanced Prevention and Research Laboratory for Dementia, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Yuriko Sobu (Y)

Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Advanced Prevention and Research Laboratory for Dementia, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Hiroyuki Ohba (H)

Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Japan.

Shingo Nishiyama (S)

Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Japan.

Norihiro Harada (N)

Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Japan.

Takeshi Ikeuchi (T)

Molecular Genetics, Niigata University Brain Research Institute, Nigata, Japan.

Hideo Tsukada (H)

Central Research Laboratory, Hamamatsu Photonics K.K., Hamamatsu, Japan.

Yasuomi Ouchi (Y)

Department of Biofunctional Imaging, Preeminent Medical Education & Research Center, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Toshiharu Suzuki (T)

Laboratory of Neuroscience, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Advanced Prevention and Research Laboratory for Dementia, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH